Benzyl-(3,3,3-trifluoro-propyl)-amine | 756469-34-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzyl-(3,3,3-trifluoro-propyl)-amine
• 英文别名: N-Benzyl-3,3,3-trifluoropropan-1-amine
• CAS: 756469-34-8
• 化学式: C₁₀H₁₂F₃N
• mdl: MFCD12771231
• 分子量: 203.207
• InChiKey: ABZBPAZWTDQHLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Benzyl-(3,3,3-trifluoro-propyl)-amine 在 三甲基铝 、 红铝 作用下， 以 甲苯 为溶剂， 反应 38.0h， 生成 Benzyl-[2-trifluoromethyl-9-(2,4,6-trimethyl-phenyl)-9H-benzo[d]imidazo[1,2-a]imidazol-3-ylmethyl]-(3,3,3-trifluoro-propyl)-amine
  参考文献：
  名称：

  Synthesis and structure–activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists

  摘要：

  8-Aryl-1,3a,8-triaza-cyclopenta[a]indenes represent a novel series of high binding affinity corticotropin-releasing factor 1 receptor antagonists. Here, we report their synthesis, SAR, and pharmacokinetic properties of compound 8e (K-i = 23 nM). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.028

文献信息

• Synthesis, structure–activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists
  作者：Xiaojun Han、Jodi A. Michne、Sokhom S. Pin、Kevin D. Burris、Lynn A. Balanda、Lawrence K. Fung、Tracey Fiedler、Kaitlin E. Browman、Matthew T. Taber、Jie Zhang、Gene M. Dubowchik

  DOI：10.1016/j.bmcl.2005.05.117

  日期：2005.9

  7-Aryl-6,7-dihydroimidazoimidazoles represent a novel series of high-affinity corticotropin-releasing factor 1 receptor antagonists. Here, we report their synthesis and SAR as well as behavioral activity of two exemplary compounds, 7b and 7k, in a mouse canopy model of anxiety.

  7-芳基-6,7-二氢咪唑并咪唑代表了一系列新的高亲和性促肾上腺皮质激素释放因子1受体拮抗剂。在这里，我们报告了它们的合成和SAR以及两个示例性化合物7b和7k在焦虑的小鼠冠层模型中的行为活性。
• [EN] INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2020023355A1

  公开（公告）日：2020-01-30

  The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

  本发明提供了以下化合物（I）的公式：其中所有变量如本文所定义。这些化合物是色氨酸2,3-二氧化酶（IDO）的抑制剂，可用作治疗增殖性疾病，如癌症、病毒感染和/或自身免疫疾病的药物。
• [EN] COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS ET PROCÉDÉS D'UTILISATION
  申请人：TANGO THERAPEUTICS INC

  公开号：WO2023146987A1

  公开（公告）日：2023-08-03

  Provided are compounds of Formula (A): Formula (A); and pharmaceutically acceptable salts thereof, and pharmaceutical compositions, processes of preparing and methods of treating thereof; wherein Ra, Ra', Ring A, Ring B, and R1are as defined in any of the embodiments described herein.

  提供了式(A)化合物：式（A）；及其药学上可接受的盐，以及其药物组合物、制备工艺和处理方法；其中 Ra、Ra'、环 A、环 B 和 R1 如本文所述的任一实施方案中所定义。
• Optimization of CRF1R binding affinity of 2-(2,4,6-trichlorophenyl)-4-trifluoromethyl-5-aminomethylthiazoles through rapid and selective parallel synthesis
  作者：Dmitry Zuev、Jodi A. Michne、Sokhom S. Pin、Jie Zhang、Matthew T. Taber、Gene M. Dubowchik

  DOI：10.1016/j.bmcl.2004.10.055

  日期：2005.1

  An efficient approach was developed to synthesize 2-(2,4,6-trichlorophenylamino)-4-trifluoromethyl-5-aminomethylthiazoles, corticotropin-releasing factor type 1 receptor (CRF1R) antagonists, by monoalkylation of amines with chloromethyl intermediate 5. The effect of variations in aminomethyl side chain of 6 on binding affinity is discussed. (C) 2004 Elsevier Ltd. All rights reserved.
• INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210299126A1

  公开（公告）日：2021-09-30

  The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.